Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .
Latest Developments forMitsubishi Chemical Holdings Corp
- Mitsubishi Chemical Holdings Corp - Announces Revision Of Targets Under Medium-Term Management Plan
- Mitsubishi Chemical Holdings unit says acquisition of US co Praxair's European businesses
- R&I affirms Mitsubishi Chemical's rating at "A" and says stable outlook -R&I
- R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I